Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

21.59 -0.90 (-4.00%)
Official Closing Price Updated: 6:30 PM EDT, Apr 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
99 100 Next >
As a Billionaire Activist Takes a Stake, Is Now the Time to Buy Pfizer Stock?
Starboard will look to turn around the struggling pharma company. 
Via The Motley Fool
Pfizer CEO Albert Bourla Set To Meet Activist Investor Starboard Value As Pressure Mounts To Revitalize Struggling Stock: Report
Pfizer Inc. CEO Albert Bourla is set to meet with activist investor Starboard Value amid growing pressure to revitalize the pharmaceutical giant's struggling share price and refine its strategic focus.... 
Via Benzinga
Pfizer to Showcase Scientific Advancements in Respiratory and Other Infectious Diseases at IDWeek 2024
From Pfizer Inc.
Via Business Wire
Fifth Avenue Animate Launches New Website to Highlight Expertise in SaaS and Finance Video Marketing
Mississauga, Ontario () October 8, 2024 -- Agency continues to deliver high-impact animated content, helping businesses explain complex concepts and drive customer engagement. 
Via Prodigy
Why Pfizer Stock Popped on Monday
Can Starboard Value and former CEO Ian Read save Pfizer stock? 
Via The Motley Fool
Behind the Scenes of Pfizer's Latest Options Trends
Via Benzinga
Key Takeaways From Pfizer Analyst Ratings
Via Benzinga
Biotech Stocks Poised For Another Big Move In Q4
The healthcare sector can be a safe haven if volatility increases. 
Via Talk Markets
Pfizer Wins London Court Battle, GSK's Respiratory Syncytial Virus Vaccine Patents Invalidated
Pfizer sees stock gains following a $1 billion investment by Starboard Value and a favorable UK court ruling invalidating two GSK RSV vaccine patents. Pfizer and GSK continue their legal battles as... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Starboard Value Reportedly Acquires $1B Stake In Pfizer As Stock Lags S&P 500 By 46%
Activist investor Starboard Value has reportedly taken a $1 billion stake in pharmaceutical giant Pfizer. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Pfizer Stock Is Moving Higher Monday: What's Driving The Action?
Pfizer Inc (NYSE:PFE) shares are on the move Monday after activist Starboard Value acquired a $1 billion stake in the pharmaceutical giant. 
Via Benzinga
Pfizer, Vista Outdoor, Duckhorn Portfolio And Other Big Stocks Moving Higher On Monday
Via Benzinga
Pfizer Jumps After Activist Investor Starboard Reportedly Takes $1 Billion Stake
Shares peaked near 62 in late 2021, but are now worth less than half of that. 
Via Investor's Business Daily
4 Reasons Pfizer Could Be a Value Play You Can't Miss
Pfizer Inc. (NYSE: PFE) hit its peak during the COVID-19 pandemic when its vaccines developed with BioNTech SE (NASDAQ: BNTX) sent shares surging up to $61.71 
Via MarketBeat
Exposures COVID-19 Product Safety
Pfizer Stock Slump: Will Starboard's Billion-Dollar Bet Spark Rebound?
Pfizer's stock has struggled due to declining demand for COVID-19 treatments, but activist investor Starboard's $1 billion stake may spark a turnaround. 
Via Benzinga
Exposures COVID-19
Wall Street Set To Start New Week Sharply Lower As Traders Brace For Key Economic Data And Fed Minutes: Why Strategist Sees Market Consolidating In Near Term
U.S. stock futures are headed lower on Monday after the jobs data-induced strength seen in the final session of last week. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Amid Pfizer's Struggles With Declining Demand For COVID-19 Treatments, Activist Investor Starboard Value Invests $1B In Pharma Giant: Report
Activist investor Starboard Value has invested approximately $1 billion in Pfizer Inc. This strategic move occurs as the pharmaceutical giant grapples with a downturn in demand for its COVID-19... 
Via Benzinga
Exposures COVID-19
3 High-Yield Dividend Stocks That Are Screaming Buys Right Now
Lower interest rates make these stand-out dividend payers must-see investments for those who want passive income. 
Via The Motley Fool
3 Magnificent Dividend Stocks to Buy in October
These dividend stocks are great picks as the fall season gets underway. 
Via The Motley Fool
Want Over $5,000 in Annual Dividends? Invest $23,000 in Each of These 3 Stocks
These stocks have yields between 5.9% and 8.5%. 
Via The Motley Fool
Election Outcome Presents Opportunity For Investors
Let’s break down the key sectors that stand to gain from a Trump or Harris presidency and explore the risks investors should be aware of heading into this election outcome. 
Via Talk Markets
Topics Government
Exposures Political
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention. 
Via Investor's Business Daily
3 Top Stocks That Could Still Rocket Higher in 2024
Upcoming Food and Drug Administration decisions could push these stocks through the roof. 
Via The Motley Fool
Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected
Guidance for the second cycle of Medicare drug price negotiations has expectations high for significant savings by 2026. 
Via Benzinga
3 Stocks Set to Benefit from Cooling Inflation Trends
Three stocks stand out in the way they can outperform the rest of the industry despite a slowing inflation rate in the economy, with high income 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Is Pfizer a Buy Right Now or a Value Trap?
Pfizer has prepared for today's challenges... and has set big goals. 
Via The Motley Fool
Johnson & Johnson's Erleada Shows Improved Overall Survival In Prostate Cancer Patients Compared To Pfizer's Drug
Johnson & Johnson reveals Erleada's 23% lower risk of death over Xtandi in a real-world study of prostate cancer patients, while also announcing a $2 billion biologics facility to support its expanding... 
Via Benzinga
3 Sensational Ultrahigh-Yield Dividend Stocks That Make for No-Brainer Buys in the 4th Quarter (and Beyond)
Three high-octane income stocks -- sporting an average yield of 6.23% -- have the necessary tools and intangibles to make their patient shareholders richer. 
Via The Motley Fool
Billionaire Ken Griffin Loaded Up on This High-Yield Dividend Stock. Should You?
A 5.8% forward-dividend yield is just one reason the hedge fund manager likes this stock. 
Via The Motley Fool
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next
HHS announced lower costs for 54 Medicare Part B drugs starting in October 2024, part of the Inflation Reduction Act's rebate program, which aims to curb rising drug prices and reduce out-of-pocket... 
Via Benzinga
Topics Economy
Exposures Interest Rates
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.